Long-Term Follow-up of Patients with Prostate Cancer and Nodal Metastases Treated by Pelvic Lymphadenectomy and Radical Prostatectomy: The Positive Impact of Adjuvant Radiotherapy

被引:159
作者
Da Pozzo, Luigi F. [1 ]
Cozzarini, Cesare [2 ]
Briganti, Alberto [1 ]
Suardi, Nazareno [1 ]
Salonia, Andrea [1 ]
Bertini, Roberto [1 ]
Gallina, Andrea [1 ]
Bianchi, Marco [1 ]
Fantini, Gemma V. [1 ]
Bolognesi, Angelo [2 ]
Fazio, Ferruccio [2 ]
Montorsi, Francesco [1 ]
Rigatti, Patrizio [1 ]
机构
[1] Univ Vita Salute San Raffaele, Dept Urol, I-20132 Milan, Italy
[2] Univ Vita Salute San Raffaele, Dept Radiotherapy, I-20132 Milan, Italy
关键词
Prostate cancer; Radical prostatectomy; Adjuvant radiotherapy; Lymph node metastases; POSTOPERATIVE RADIOTHERAPY; ANATOMICAL EXTENT; LYMPH-NODES; DISSECTION; PROGRESSION; RADIATION; MEN; EXPERIENCE; SURVIVAL; THERAPY;
D O I
10.1016/j.eururo.2009.01.046
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
100201 [内科学]; 100221 [泌尿外科学];
摘要
Background: Recent large, prospective, randomised studies have demonstrated that adjuvant radiotherapy (RT) is a safe and effective procedure for preventing disease recurrence in locally advanced prostate cancer (PCa) patients. However, no study has ever tested the role of adjuvant RT in node-positive patients after radical prostatectomy (RP). Objective: We hypothesised that adjuvant RT with early hormone therapy (HT) might improve long-term outcomes of patients with PCa and nodal metastases treated with RP and extended pelvic lymph node dissection (ePLND). Design, setting, and participants: This retrospective study included 250 consecutive patients with pathologic lymph node invasion. We assessed factors predicting long-term biochemical recurrence (BCR)-free and cancer-specific survival (CSS) in node-positive PCa patients treated with RP, ePLND, and adjuvant treatments between 1988 and 2002 in a tertiary academic centre. Intervention: All patients received adjuvant treatments according to the treating physician after detailed patient information: 129 patients (51.6%) were treated with a combination of RT and HT, while 121 patients (48.4%) received adjuvant HT alone. Measurements: BCR-free survival and CSS in patients with node-positive PCa. Results and limitations: mean follow-up was 95.9 mo (median: 91.2). BCR-free survival and CSS rates at 5, 8, and 10 yr were 72%, 61%, 53% and 89%, 83%, 80%, respectively. In multivariable Cox regression models, adjuvant RT and the number of positive nodes were independent predictors of BCR-free survival (p = 0.002 and p = 0.003, respectively) as well as of CSS (p = 0.009 and p = 0.01, respectively). Moreover, there was significant gain in predictive accuracy when adjuvant RT was included in multivariable models predicting BCR-free survival and CSS (gain: 3.3% and 3%, respectively; all p < 0.001). Conclusions: Our data showed excellent long-term outcome for node-positive PCa patients treated with radical surgery plus adjuvant treatments. This study is the first to report a significant protective role for adjuvant RT in BCR-free survival and CSS of node-positive patients. (C) 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1003 / 1011
页数:9
相关论文
共 31 条
[1]
Anatomical extent of lymph node dissection: Impact on men with clinically localized prostate cancer [J].
Allaf, ME ;
Palapattu, GS ;
Trock, BJ ;
Carter, HB ;
Walsh, PC .
JOURNAL OF UROLOGY, 2004, 172 (05) :1840-1844
[2]
Is a limited lymph node dissection an adequate staging procedure for prostate cancer? [J].
Bader, P ;
Burkhard, FC ;
Markwalder, R ;
Studer, UE .
JOURNAL OF UROLOGY, 2002, 168 (02) :514-518
[3]
Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? [J].
Bader, P ;
Burkhard, FC ;
Markwalder, R ;
Studer, UE .
JOURNAL OF UROLOGY, 2003, 169 (03) :849-854
[4]
Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph node's retrieved in cystectomy specimens [J].
Bochner, BH ;
Herr, HW ;
Reuter, VE .
JOURNAL OF UROLOGY, 2001, 166 (06) :2295-2296
[5]
Postoperative radiotherapy after radical prostatectomy:: a randomised controlled trial (EORTC trial 22911) [J].
Bolla, M ;
van Poppel, H ;
Collette, L ;
van Cangh, P ;
Vekemans, K ;
Da Pozzo, L ;
de Reijke, TM ;
Verbaeys, A ;
Bosset, JF ;
van Velthoven, R ;
Maréchal, JM ;
Scalliet, P ;
Haustermans, K ;
Piérart, M .
LANCET, 2005, 366 (9485) :572-578
[6]
Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era [J].
Boorjian, Stephen A. ;
Thompson, R. Houston ;
Siddiqui, Sameer ;
Bagniewski, Stephanie ;
Bergstralh, Erik J. ;
Karnes, R. Jeffrey ;
Frank, Igor ;
Blute, Michael L. .
JOURNAL OF UROLOGY, 2007, 178 (03) :864-870
[7]
Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy [J].
Briganti, Alberto ;
Chun, Felix K. -H. ;
Salonia, Andrea ;
Zanni, Giuseppe ;
Scattoni, Vincenzo ;
Valiquette, Luc ;
Rigatti, Patrizio ;
Montorsi, Francesco ;
Karakiewicz, Pierre I. .
EUROPEAN UROLOGY, 2006, 49 (06) :1019-1027
[8]
Two Positive Nodes Represent a Significant Cut-off Value for Cancer Specific Survival in Patients with Node Positive Prostate Cancer. A New Proposal Based on a Two-Institution Experience on 703 Consecutive N plus Patients Treated with Radical Prostatectomy, Extended Pelvic Lymph Node Dissection and Adjuvant Therapy [J].
Briganti, Alberto ;
Karnes, Jeffrey R. ;
Da Pozzo, Luigi Filippo ;
Cozzarini, Cesare ;
Gallina, Andrea ;
Suardi, Nazareno ;
Bianchi, Marco ;
Freschi, Massimo ;
Doglioni, Claudio ;
Fazio, Ferruccio ;
Rigatti, Patrizio ;
Montorsi, Francesco ;
Blute, Michael L. .
EUROPEAN UROLOGY, 2009, 55 (02) :261-270
[9]
DETECTION OF ORGAN-CONFINED PROSTATE-CANCER IS INCREASED THROUGH PROSTATE-SPECIFIC ANTIGEN-BASED SCREENING [J].
CATALONA, WJ ;
SMITH, DS ;
RATLIFF, TL ;
BASLER, JW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (08) :948-954
[10]
Cheng L, 2001, CANCER-AM CANCER SOC, V91, P66, DOI 10.1002/1097-0142(20010101)91:1<66::AID-CNCR9>3.0.CO